NON-INSULIN DRUGS IN DIABETES MELLITUS TYPE 1 (METFORMINE, IDPP-4, PRAMLINTIDA, AGLP-1, ISGLT-2)
There are approximately 25 million patients with type 1 diabetes mellitus (DM1) in the world, a figure that would triple in 2050. Although the optimum is to reach A1c levels <7% to avoid and / or slow down the onset / evolution of chronic complications, only 30% of patients achieve this. Furtherm...
Main Author: | León Litwak |
---|---|
Format: | Article |
Language: | Spanish |
Published: |
Sello Editorial Lugones
2020-07-01
|
Series: | Revista de la Sociedad Argentina de Diabetes |
Subjects: | |
Online Access: | https://www.revistasad.com/index.php/diabetes/article/view/230 |
Similar Items
-
Symposium 12: People with type 2 diabetes treated with insulin: evidence to associate non-insulin drugs.
by: Matías Re
Published: (2022-09-01) -
Symposium 7: Pharmacological algotuhm in diabetes mellitus type 2 without previous events
by: Pablo Javier Ávila
Published: (2022-09-01) -
6 voices in 10 minutes: When do we choose SGLT2i or GLP1ag?
by: Cristina Faingold
Published: (2020-11-01) -
Aspectos fisiopatológicos en el paciente con obesidad y diabetes mellitus tipo 1
by: León Litwak
Published: (2023-08-01) -
Symposium 2: What have CVOT taught us about microvascular impact in T2DM?
by: Fabiana Vázquez
Published: (2022-09-01)